<DOC>
	<DOCNO>NCT00567788</DOCNO>
	<brief_summary>This randomized observer-masked cross-over study compare intraocular pressure ( IOP ) reduce effect latanoprost bimatoprost subject chronic angle closure glaucoma ( CACG ) raise IOP . Study subject randomize receive either latanoprost daily bimatoprost daily 6 week , cross medication another 6 week . The IOP-reducing effect medication assess reduction IOP medication compare baseline . The study carry least 2 Singapore hospital .</brief_summary>
	<brief_title>Comparison Bimatoprost Latanoprost Patients With Chronic Angle-Closure Glaucoma : A Randomized Cross-Over Study</brief_title>
	<detailed_description>Study eye define eye ( ) fulfil inclusion criterion none exclusion criterion . The IOP measure Goldmann applanation tonometry . The IOP every visit take one examiner ( mask ) use slit lamp tonometer . Three consecutive reading take time mean three value use statistical analysis . The examiner aware treatment patient . The scale tonometer conceal examiner , IOP value read assistant examiner determines end point tonometry . At Baseline visit last visit Treatment period ( Day 0 , 42 84 ) , IOP measure 9 5 pm . On Day 14 56 , IOP measure 9 AM . Thus , IOP measure clinic 9 AM , approximately 13 hour would elapse even dose . This coincide approximate peak effect bimatoprost latanoprost . The IOP reading 5 PM approximate trough latanoprost bimatoprost . The IOP end Treatment period 6 week ( Day 42 84 ) utilized primary endpoint comparison mean IOPs two treatment group compare baseline ( Day 0 ) . For , reason , complete 6-week assessment , last IOP measure carry forward provide endpoint . However , number case within treatment group also report . Prior trial , patient undergo clinical examination eye test determine eligibility . After enrolled trial , patient randomize receive either latanoprost bimatoprost . They subject list test ( detail schedule procedure Appendix A ) baseline day ( Day 0 ) instruct first eye application start 8pm day . For 6 week , patient assign latanoprost treatment group administer latanoprost 0.005 % evening . Patients assign bimatoprost group administer 0.03 % bimatoprost daily ( even ) . Study visit Day 14 ( Visit 2 ) Day 42 ( Visit 3 ) . After 6 week , patient cross medication . Patients undergo exactly regimen examination clinic visit Treatment period I . Study visit Day 56 ( Visit 4 ) Day 84 ( Visit 5 ) .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Angle-Closure</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>1 . Unilateral bilateral CACG 2 . Age equal 40 year old 3 . Informed consent obtain prestudy visit patient 1 . Secondary glaucoma uveitic neovascular glaucoma 2 . One eye eligible fellow eye unsuitable glaucoma treatment trial 3 . IOP &gt; 36 mmHg Prestudy visit 4 . Advanced glaucoma risk progression . This defined vertical cupdisc ratio &gt; 0.9 and/or central visual field loss sensitivity &lt; 10 dB 4 visual field test point closest fixation 5 . Ocular infection inflammation ( except relate peripheral iridotomy ) within 3 month prestudy visit 6 . On two antiglaucoma medication 7 . Previous intraocular surgery apart laser peripheral iridotomy 8 . Previous trauma eye , angle damage 9 . Ocular treatment steroid nonsteroidal antiinflammatory medication within 1 month prestudy visit . 10 . Use contact lens . 11 . Cornea infection cornea abnormality . 12 . Ocular disease dry eye retinal pathology . 13 . Oral medication , diuretic , know affect IOP . 14 . Cerebrovascular , hepatic , renal , metabolic disease . 15 . Known allergy benzalkonium , component latanoprost/bimatoprost . 16 . History noncompliance . 17 . Women pregnant , lactating , childbearing potential use adequate contraception . 18 . Participated another therapeutic medication study within last 1 month .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Glaucoma , angle-closure</keyword>
</DOC>